AI Medical Technology today announced the successful closure of an oversubscribed bridge financing round worth SEK12 (US$1m). Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders. The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis of malignant melanomas. Results from a prospective, multicentre, peer-reviewed clinical trial recently published in the British Journal of Dermatology showed that Dermalyser had a remarkably high diagnostic precision1, outperforming both primary care physicians and specialist dermatologists. Christoffer Ekström, CEO of AI Medical Technology comments: “I am delighted to be raising more money to support the ongoing development of Dermalyser. To have yet another oversubscribed round just … Continue reading Skin cancer diagnostic company AI Medical Technology raises SEK12m (US$1m) via an oversubscribed bridge financing round in anticipation of a significant Series A later this year